Mindfulness-based interventions (MBIs) have been previously linked with improved cognition and reduced stress, anxiety, and depression. Yet, traditional MBIs are lengthy and resource intensive. Brief and online MBIs represent a bridge into more extensive practice—but questions of whether these protocols improve cognition and affect remain. The present experiment used a randomized longitudinal...
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potential therapeutic applications, particularly in the rapid and sustained treatment of depression. However, the potent acute psychedelic effects of psilocybin necessitate a deeper understanding of the neural mechanisms underlying its action. In this study,...
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...
ObjectivesTo review the available evidence, key deliberations, and potential influences behind the Pharmaceutical Benefits Advisory Committee's (PBAC's) conditional recommendation for esketamine to be listed on the Pharmaceutical Benefits Scheme (PBS).ConclusionsThis paper forms part 2 of the esketamine story in Australia-its handling by the Therapeutic Goods Administration (TGA) and,...
Molecular PsychiatryJuly 7, 2025Dongsun Park, Gwangho Lee, Won-Gyu Lee et al.7 citations
Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting 5-HT2A receptors, both enhance...
Abstract Objectives Over the past two decades, mindfulness research conducted in school settings has grown rapidly, with a range of programs now in circulation. Given this burgeoning research area, the present review aimed to evaluate the effectiveness of school-based mindfulness programs on student psychological, social-emotional, cognitive and educational outcomes. Method Published and...
Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, and substance use disorders. However, perceptions of these treatments vary globally. This study explores the familiarity, attitudes, and perceptions of Jordanian physicians and medical students toward psychedelic substances, addressing a gap in Middle...
LSD (lysergic Acid Diethylamide), a psychedelic compound, has been investigated in recent studies for the treatment of mental disorders. We analyzed the efficacy and safety of LSD in the treatment of mental disorders and substance use disorders in adult patients. We searched Embase, PubMed, Scopus, PsycINFO, the Cochrane Library, CENTRAL, BVS, EBSCO, Epistemonikos, and the grey literature for...
“RELIEF OCEAN” is a poetic rumination on the spiritual/mystical possibilities that swim alongside affective states experienced during depression and sickness, but also in psychedelia, art, queer love and friendship, and in grief. This essay begins with a reflection on the writer’s artistic collaboration with his late ex-boyfriend Billy, who died in December 2024 after a multiyear battle with...
Promising results have emerged in the use of psychedelic drugs for treating depression. Despite multiple neural models attempting to elucidate the acute psychedelic experience, and an increased focus on potential mechanisms driving persistent change, the connections between the acute state and the enduring therapeutic outcomes remain elusive. This targeted review aims to bridge this gap by...